Nutriband Secures $5.3 Million Through Warrant Exercises to Advance Abuse-Deterrent Fentanyl Patch Development
TL;DR
Nutriband's $5.3M warrant exercise funds AVERSA Fentanyl development, positioning it as the first abuse-deterrent opioid patch with $80-200M peak annual sales potential.
Nutriband raised $5,306,000 through warrant exercises at $6.43 per share to complete clinical trials and submit an NDA for AVERSA Fentanyl to the FDA.
AVERSA Fentanyl's abuse-deterrent technology prevents opioid misuse and accidental exposure, making opioid therapy safer for patients and communities worldwide.
Nutriband is developing the world's first abuse-deterrent fentanyl patch using innovative AVERSA technology to transform transdermal drug delivery safety.
Found this article helpful?
Share it with your network and spread the knowledge!
Nutriband Inc. (NASDAQ: NTRB) has generated $5,306,000 in proceeds through the exercise of warrants at a strike price of $6.43, providing critical funding for the advancement of its AVERSA Fentanyl transdermal patch. The capital infusion will support the remaining clinical development and submission of a New Drug Application to the U.S. Food and Drug Administration for what could become the world's first opioid patch with abuse deterrent properties.
The financial backing comes at a crucial time for the pharmaceutical development sector, particularly for companies addressing the ongoing opioid crisis through innovative abuse-deterrent technologies. According to a 2022 Health Advances market analysis report cited in the company's announcement, AVERSA Fentanyl is estimated to reach peak annual U.S. sales between $80 million and $200 million, representing significant commercial potential in the pain management market.
Nutriband's AVERSA technology platform represents a novel approach to combating prescription drug abuse, which remains a critical public health concern. The technology can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. This development is particularly important given the persistent challenges surrounding opioid medications and the need for safer alternatives that maintain therapeutic benefits while reducing abuse risks.
The warrant exercise demonstrates investor confidence in Nutriband's technology and development pipeline during a period when regulatory scrutiny of abuse-deterrent formulations remains high. Successful development and approval of AVERSA Fentanyl could establish new standards for transdermal drug delivery systems and provide healthcare providers with additional tools for managing pain while addressing safety concerns.
For investors and industry observers, the funding milestone and ongoing development progress can be tracked through the company's newsroom available at https://ibn.fm/NTRB. The pharmaceutical industry continues to monitor advancements in abuse-deterrent technologies as regulatory agencies and healthcare providers seek solutions to balance pain management needs with public safety considerations.
Curated from InvestorBrandNetwork (IBN)
